Expert Analysis From Boston: HCV Management Strategies With Approved Agents

[Guest guest]

*CCO is an independent medical education company that provides state-of-the-art

medical information to healthcare professionals through conference coverage and

other educational programs.

CME/CE-Certified Expert AnalysisClick to AccessAdvances in HCV Management

Strategies With Approved AgentsCCO Independent Conference Coverage of the2007

Annual Meeting of the American Association for the Study of Liver

Diseases*November 2-6, 2007 | Boston, Massachusetts

Dear colleague,

Following the liver disease meeting in Boston, I had the opportunity to meet

with L. Shiffman, MD, and Mark S. Sulkowski, MD, to discuss the latest

advances in HCV management strategies with approved agents. Our discussion is

now available on the Clinical Care Options Web site as a CME/CE-certified Expert

Analysis.

Topics include:

Baseline Predictors of Response to Approved Agents in HCV Patients

Predictive Value of On-Treatment Responses for Sustained Virologic Response

Strategies to Improve Response to Approved HCV Treatments

Retreatment Strategies for Previous Peginterferon alfa/Ribavirin Nonresponders

To read about these latest advances presented at the liver disease meeting,

click here.

I encourage you to review this Expert Analysis for data important to your

clinical practice.

Regards,

T. Chung, MDAssociate Professor of MedicineDepartment of MedicineHarvard

Medical SchoolDirector of HepatologyMedical Director, Liver Transplant

ProgramMassachusetts General HospitalBoston, Massachusetts

This Expert Analysis is located online

at:http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007.aspx

Physicians:Jointly sponsored by Postgraduate Institute for Medicine and Clinical

Care Options, LLC.

Nurses:Nursing contact hours provided through the cosponsorship of Postgraduate

Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute

for Medicine is accredited as a provider of continuing nursing education by the

American Nurses Credentialing Center's Commission on Accreditation.

Pharmacists:Postgraduate Institute for Medicine is accredited by the

Accreditation Council for Pharmacy Education as a provider of continuing

pharmacy education. Pharmacy credit hours provided through the cosponsorship of

Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Release date: December 20, 2007Expiration date: December 19, 2008

Supported by educational grants from Bristol-Myers Squibb, Gilead Sciences,

Roche, Schering-Plough, and Vertex.

Unsubscribe | Not a member yet? Click here | RSS | Hepatitis Podcasts |

Bookstore

To ensure you receive Clinical Care Options educational materials by

email,please add info@... to your contacts or address book.

Copyright 2008 Clinical Care Options, LLC. All rights reserved. 1894 Preston

White Drive, Suite 110, Reston, VA 20191-5433

_________________________________________________________________

Watch “Cause Effect,” a show about real people making a real difference.

http://im.live.com/Messenger/IM/MTV/?source=text_watchcause

[Guest guest]

*CCO is an independent medical education company that provides state-of-the-art

medical information to healthcare professionals through conference coverage and

other educational programs.

CME/CE-Certified Expert AnalysisClick to AccessAdvances in HCV Management

Strategies With Approved AgentsCCO Independent Conference Coverage of the2007

Annual Meeting of the American Association for the Study of Liver

Diseases*November 2-6, 2007 | Boston, Massachusetts

Dear colleague,

Following the liver disease meeting in Boston, I had the opportunity to meet

with L. Shiffman, MD, and Mark S. Sulkowski, MD, to discuss the latest

advances in HCV management strategies with approved agents. Our discussion is

now available on the Clinical Care Options Web site as a CME/CE-certified Expert

Analysis.

Topics include:

Baseline Predictors of Response to Approved Agents in HCV Patients

Predictive Value of On-Treatment Responses for Sustained Virologic Response

Strategies to Improve Response to Approved HCV Treatments

Retreatment Strategies for Previous Peginterferon alfa/Ribavirin Nonresponders

To read about these latest advances presented at the liver disease meeting,

click here.

I encourage you to review this Expert Analysis for data important to your

clinical practice.

Regards,

T. Chung, MDAssociate Professor of MedicineDepartment of MedicineHarvard

Medical SchoolDirector of HepatologyMedical Director, Liver Transplant

ProgramMassachusetts General HospitalBoston, Massachusetts

This Expert Analysis is located online

at:http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007.aspx

Physicians:Jointly sponsored by Postgraduate Institute for Medicine and Clinical

Care Options, LLC.

Nurses:Nursing contact hours provided through the cosponsorship of Postgraduate

Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute

for Medicine is accredited as a provider of continuing nursing education by the

American Nurses Credentialing Center's Commission on Accreditation.

Pharmacists:Postgraduate Institute for Medicine is accredited by the

Accreditation Council for Pharmacy Education as a provider of continuing

pharmacy education. Pharmacy credit hours provided through the cosponsorship of

Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Release date: December 20, 2007Expiration date: December 19, 2008

Supported by educational grants from Bristol-Myers Squibb, Gilead Sciences,

Roche, Schering-Plough, and Vertex.

Unsubscribe | Not a member yet? Click here | RSS | Hepatitis Podcasts |

Bookstore

To ensure you receive Clinical Care Options educational materials by

email,please add info@... to your contacts or address book.

Copyright 2008 Clinical Care Options, LLC. All rights reserved. 1894 Preston

White Drive, Suite 110, Reston, VA 20191-5433

_________________________________________________________________

Watch “Cause Effect,” a show about real people making a real difference.

http://im.live.com/Messenger/IM/MTV/?source=text_watchcause

[Guest guest]

*CCO is an independent medical education company that provides state-of-the-art

medical information to healthcare professionals through conference coverage and

other educational programs.

CME/CE-Certified Expert AnalysisClick to AccessAdvances in HCV Management

Strategies With Approved AgentsCCO Independent Conference Coverage of the2007

Annual Meeting of the American Association for the Study of Liver

Diseases*November 2-6, 2007 | Boston, Massachusetts

Dear colleague,

Following the liver disease meeting in Boston, I had the opportunity to meet

with L. Shiffman, MD, and Mark S. Sulkowski, MD, to discuss the latest

advances in HCV management strategies with approved agents. Our discussion is

now available on the Clinical Care Options Web site as a CME/CE-certified Expert

Analysis.

Topics include:

Baseline Predictors of Response to Approved Agents in HCV Patients

Predictive Value of On-Treatment Responses for Sustained Virologic Response

Strategies to Improve Response to Approved HCV Treatments

Retreatment Strategies for Previous Peginterferon alfa/Ribavirin Nonresponders

To read about these latest advances presented at the liver disease meeting,

click here.

I encourage you to review this Expert Analysis for data important to your

clinical practice.

Regards,

T. Chung, MDAssociate Professor of MedicineDepartment of MedicineHarvard

Medical SchoolDirector of HepatologyMedical Director, Liver Transplant

ProgramMassachusetts General HospitalBoston, Massachusetts

This Expert Analysis is located online

at:http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007.aspx

Physicians:Jointly sponsored by Postgraduate Institute for Medicine and Clinical

Care Options, LLC.

Nurses:Nursing contact hours provided through the cosponsorship of Postgraduate

Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute

for Medicine is accredited as a provider of continuing nursing education by the

American Nurses Credentialing Center's Commission on Accreditation.

Pharmacists:Postgraduate Institute for Medicine is accredited by the

Accreditation Council for Pharmacy Education as a provider of continuing

pharmacy education. Pharmacy credit hours provided through the cosponsorship of

Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Release date: December 20, 2007Expiration date: December 19, 2008

Supported by educational grants from Bristol-Myers Squibb, Gilead Sciences,

Roche, Schering-Plough, and Vertex.

Unsubscribe | Not a member yet? Click here | RSS | Hepatitis Podcasts |

Bookstore

To ensure you receive Clinical Care Options educational materials by

email,please add info@... to your contacts or address book.

Copyright 2008 Clinical Care Options, LLC. All rights reserved. 1894 Preston

White Drive, Suite 110, Reston, VA 20191-5433

_________________________________________________________________

Watch “Cause Effect,” a show about real people making a real difference.

http://im.live.com/Messenger/IM/MTV/?source=text_watchcause

[Guest guest]

*CCO is an independent medical education company that provides state-of-the-art

medical information to healthcare professionals through conference coverage and

other educational programs.

CME/CE-Certified Expert AnalysisClick to AccessAdvances in HCV Management

Strategies With Approved AgentsCCO Independent Conference Coverage of the2007

Annual Meeting of the American Association for the Study of Liver

Diseases*November 2-6, 2007 | Boston, Massachusetts

Dear colleague,

Following the liver disease meeting in Boston, I had the opportunity to meet

with L. Shiffman, MD, and Mark S. Sulkowski, MD, to discuss the latest

advances in HCV management strategies with approved agents. Our discussion is

now available on the Clinical Care Options Web site as a CME/CE-certified Expert

Analysis.

Topics include:

Baseline Predictors of Response to Approved Agents in HCV Patients

Predictive Value of On-Treatment Responses for Sustained Virologic Response

Strategies to Improve Response to Approved HCV Treatments

Retreatment Strategies for Previous Peginterferon alfa/Ribavirin Nonresponders

To read about these latest advances presented at the liver disease meeting,

click here.

I encourage you to review this Expert Analysis for data important to your

clinical practice.

Regards,

T. Chung, MDAssociate Professor of MedicineDepartment of MedicineHarvard

Medical SchoolDirector of HepatologyMedical Director, Liver Transplant

ProgramMassachusetts General HospitalBoston, Massachusetts

This Expert Analysis is located online

at:http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007.aspx

Physicians:Jointly sponsored by Postgraduate Institute for Medicine and Clinical

Care Options, LLC.

Nurses:Nursing contact hours provided through the cosponsorship of Postgraduate

Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute

for Medicine is accredited as a provider of continuing nursing education by the

American Nurses Credentialing Center's Commission on Accreditation.

Pharmacists:Postgraduate Institute for Medicine is accredited by the

Accreditation Council for Pharmacy Education as a provider of continuing

pharmacy education. Pharmacy credit hours provided through the cosponsorship of

Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Release date: December 20, 2007Expiration date: December 19, 2008

Supported by educational grants from Bristol-Myers Squibb, Gilead Sciences,

Roche, Schering-Plough, and Vertex.

Unsubscribe | Not a member yet? Click here | RSS | Hepatitis Podcasts |

Bookstore

To ensure you receive Clinical Care Options educational materials by

email,please add info@... to your contacts or address book.

Copyright 2008 Clinical Care Options, LLC. All rights reserved. 1894 Preston

White Drive, Suite 110, Reston, VA 20191-5433

_________________________________________________________________

Watch “Cause Effect,” a show about real people making a real difference.

http://im.live.com/Messenger/IM/MTV/?source=text_watchcause